Welcome to the e-CCO Library!

DOP021: Long-term efficacy of autologous haematopoietic stem cells transplantation for refractory Crohns disease: 10 years of Milan experience without CD34+ cell selection
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Cassinotti*1, F. Onida2, C. Annaloro2, G. Saporiti2, M. Fichera1, M. Daperno3, B. Motta2, P. Fociani4, E. Tagliaferri2, G. Sampietro5, D. Vincenti2, A. Gregorini2, G. Maconi1, M. Nebuloni6, A. Cortelezzi2, S. Ardizzone1

Created: Friday, 22 February 2019, 9:49 AM
DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: a randomised controlled trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.E. Kreijne1*, M.R. Lie1, G. Dijkstra2, M. Löwenberg3, G. van Assche4, R.L. West5, D. van Noord5, A.A. van der Meulen - de Jong6, B.E. Hansen1,7, A.C. de Vries1, C.J. van der Woude1

Created: Thursday, 21 February 2019, 9:14 AM
DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: A randomised controlled trial
Year: 2018
Source: ECCO'18 Vienna
Authors: Kreijne Joany E.
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP022: Targeting immune cell metabolism: LYC-30937, a novel therapeutic approach for inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Carter1, R. Morgan1, C. Lesch1, M. Spahr1, L. Franchi2, I. Monteleone3, G. Monteleone3, G. Glick2, H. J. Wilkins1, P. Higgins*2

Created: Friday, 22 February 2019, 9:49 AM
DOP022: Vedolizumab (VDZ) and anti-α treatment effectiveness in patients with IBD treated in Germany: A retrospective chart review
Year: 2017
Source: ECCO'17 Barcelona
Authors: Ehehalt R.
Crohn's disease, Anti-TNF agents,Vedolizumab
Files: 1
DOP022: Vedolizumab and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: a retrospective chart review
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ehehalt R.*1, Schubert S.2, Stein D.3, Lambrelli D.4, Bassel M.5, Orzechowski H.-D.6, Minda K.7, Khalid J.M.8

Created: Wednesday, 20 February 2019, 10:36 AM
DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Dulai P.*1, Meserve J.1, Hartke J.2, Chilukuri P.2, Chaudrey K.3, Koliani-Pace J.L.4, Kochhar G.5, Parikh M.P.5, Shmidt E.6, Hirten R.6, Luo M.7, Barocas M.7, Lasch K.7, Sultan K.8, Swaminath A.9, Bohm M.10, Lukin D.11, Hudesman D.12, Shen B.5, Siegel C.A.4, Sands B.E.6, Colombel J.-F.6, Kane S.3, Loftus Jr. E.V.3, Singh S.1, Sandborn W.J.1, Boland B.S.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP023: Safety and efficacy of a novel IV targeted pegylated liposomal prednisolone product (Nanocort): results from a phase 2a study in patients with active ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. van Assche1, P. Rutgeerts1, M. Ferrante1, M. Noman1, H. Fidder2, B. Oldenburg2, J. Metselaar3, 4, S. Vermeire*1

Created: Friday, 22 February 2019, 9:49 AM
DOP023: Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials
Year: 2018
Source: ECCO '18 Vienna
Authors:

W.J. Sandborn1, J. Panés2*, G.R. D’Haens3, B.E. Sands4, C. Su5, M. Moscariello5, T.V. Jones5, R.D. Pedersen5, G.S. Friedman5, N. Lawendy5, G. Chan5

Created: Thursday, 21 February 2019, 9:14 AM
DOP024: Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

V. Sinniger1, 2, 3, S. Pellissier3, 4, D. Hoffmann5, C. Trocmé6, L. Vercueil3, 7, 
D. Clarençon3, 8, B. Bonaz*3, 9

Created: Friday, 22 February 2019, 9:49 AM
DOP024: Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases
Year: 2016
Source: ECCO'16 DOP
Authors: Bonaz B.
Crohn's Disease
Files: 1
DOP024: Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Hanauer1, R. Panaccione2, S. Danese3, A. Cheifetz4, W. Reinisch5*, P.D.R. Higgins6, D.A. Woodworth7, H. Zhang7, G.S. Friedman7, N. Lawendy7, D. Quirk7, C.I. Nduaka7, C. Su7

Created: Thursday, 21 February 2019, 9:14 AM
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infections
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ng S.C.*1, Palo W.2, Blake A.3, Rana-Khan Q.4, Bhayat F.5

Created: Wednesday, 20 February 2019, 10:36 AM
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infections
Year: 2017
Source: ECCO'17 Barcelona
Authors: Ng S.
Concomitant infections, Vedolizumab
Files: 1
DOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

W. Sandborn1, 2, B. Bhandari3, R. Fogel4, J. Onken5, E. Yen6, E. Huntzicker6, Y. Xin6, D. French6, J. Silverman6, B. Kanwar6, M. Subramanian6, J. McHutchison6, S. Lee7, L. Shackelton8, L. Stitt8, R. Pai9, B. Levesque*2, G. D’Haens10, 11, B. Feagan8, 12

Created: Friday, 22 February 2019, 9:49 AM